When it comes to treating diseases, the author of today’s article notes “It seems that there is a shift away from treating symptoms with chemical compounds and towards attacking diseases within the body.” This shift to biotech solutions is even seen in ophthalmology, where the author highlights one niche company whose stock he intends to buy – and which he recommends as a high risk/high reward way for more aggressive investors to play the shift to biotech solutions. For more, CLICK HERE.